{"nctId":"NCT00448279","briefTitle":"THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.","startDateStruct":{"date":"2007-04"},"conditions":["Breast Cancer"],"count":58,"armGroups":[{"label":"Chemotherapy Alone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Chemotherapy"]},{"label":"Chemotherapy, Trastuzumab","type":"EXPERIMENTAL","interventionNames":["Drug: trastuzumab","Drug: Chemotherapy"]}],"interventions":[{"name":"trastuzumab","otherNames":["Herceptin"]},{"name":"Chemotherapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* female patients, \\>=18 years of age;\n* metastatic breast cancer;\n* HER2 overexpression (IHC 3+ and/or FISH positive);\n* disease progression during or after previous 1st line chemotherapy plus Herceptin;\n* scheduled to receive 2nd line chemotherapy.\n\nExclusion Criteria:\n\n* incompatibility with previous Herceptin therapy;\n* pregnancy.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS) - Percentage of Participants With an Event","description":"PFS was defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Participants were censored at the last tumour evaluation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.6","spread":null},{"groupId":"OG001","value":"58.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Progression-Free Survival - Time to Event","description":"The median time from randomization to PFS event. Participants were censored at the last tumour evaluation.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"9.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) - Percentage of Participants With an Event","description":"OS was defined as the time from randomization to the date of death from any cause. Participants were censored at the last contact date at which the participant was known to be alive.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55.2","spread":null},{"groupId":"OG001","value":"34.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival - Time to Event","description":"The median time from randomization to OS event. Participants were censored at the last contact date at which the participant was known to be alive.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null},{"groupId":"OG001","value":"26.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Best Overall Response (BOR)","description":"BOR was defined as the best objective response observed during the treatment period according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete response (CR): disappearance of all target lesions (TLs), with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 millimeters (mm). Partial response (PR): at least a 30 percent (%) decrease in the sum of diameters of TLs, taking as reference the BL sum diameters. Progressive disease (PD): at least a 20% increase in the sum of diameters of TLs, taking as a reference the smallest sum on study (this included the BL sum if that is the smallest on study). In addition to the relative increase in 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. Stable disease (SD) was defined as neither sufficient shrinkages to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6","spread":null},{"groupId":"OG001","value":"20.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","spread":null},{"groupId":"OG001","value":"24.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","spread":null},{"groupId":"OG001","value":"13.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.0","spread":null},{"groupId":"OG001","value":"31.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Best Overall Response of CR or PR","description":"BOR was defined as the best objective response observed during the treatment period according to RECIST version 1.1. CR: disappearance of all TLs, with any pathological lymph nodes (whether target or non-target) having a reduction in short axis to less than 10 mm. PR: at least a 30% decrease in the sum of diameters of TLs, taking as reference the BL sum diameters. PD: at least a 20% increase in the sum of diameters of TLs, taking as a reference the smallest sum on study (this included the BL sum if that is the smallest on study). In addition to the relative increase in 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. SD: neither sufficient shrinkages to qualify for PR, nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6","spread":null},{"groupId":"OG001","value":"31.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":26},"commonTop":["Neutropenia","Leukopenia","Other - unspecified","Nausea","Fever"]}}}